Hartford Healthcare’s team won’t be quite as strong after an upcoming manager departure, so its People rating has been lowered to Above Average from High, and the Morningstar Analyst Ratings of all its share classes have been downgraded to Bronze as a result.
Hartford Healthcare R3 HGHRX
NAV / 1-Day Return
44.88
/
0.38
%
Total Assets
1.7 Bil
Adj. Expense Ratio
Adjusted Expense Ratio excludes certain variable investment-related expenses, such as interest from borrowings and dividends on borrowed securities, allowing for more consistent cost comparisons across funds.
1.600%
Expense Ratio
1.600%
Fee Level
Above Average
Longest Manager Tenure
21.15
years
Category
Health
Investment Style
Large GrowthMin. Initial Investment
0
Status
Open
TTM Yield
0.00%
Turnover
49%
Premium
Morningstar’s Analysis
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
The Morningstar Analysis section contains a thorough evaluation of an investment’s merits and drawbacks and often discusses the most important or decisive factors leading to the fund’s overall rating.
Will HGHRX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
Process Pillar
The Process Pillar is our assessment of how sensible, clearly defined, and repeatable HGHRX’s performance objective and investment process is for both security selection and portfolio construction.
People Pillar
The People Pillar is our evaluation of the HGHRX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of HGHRX’s parent organization’s priorities and whether they’re in line with investors’ interests.
Not quite as attractive after a longtime manager leaves in mid-2021.
